Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (38): 7197-7200.doi: 10.3969/j.issn.1673-8225.2011.38.040

Previous Articles     Next Articles

Sustained-release anti-tumor agent in interventional treatment of liver cancer

Pan Yan-kang, Huang Min, Liu Yu-heng   

  1. Department of Intervention, Clinical Tumor Center, People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning  315700, Guangxi Zhuang Autonomous Region, China
  • Received:2011-05-05 Revised:2011-08-12 Online:2011-09-17 Published:2011-09-17
  • About author:Pan Yan-kang, Attending physician, Department of Intervention, Clinical Tumor Center, People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning 315700, Guangxi Zhuang Autonomous Region, China longtenhe1965@ yahoo.com.cn

PDF

462

Abstract:

BACKGROUND: Direct injection of sustained-release chemotherapy provides a new way to tumor treatment.
OBJECTIVE: To evaluate the application of sustained-release anti-tumor agents in liver cancer and to find a reasonable treatment.
METHODS: A computer based search of relevant articles published 1993-01/2010-12 were retrieved by using the keywords of “liver cancer, implantation of chemotherapy, sustained release implants, chemicals” in Chinese and English. Repetitive articles and Meta analysis were excluded, and finally 29 articles were included in result analysis.
RESULTS AND CONCLUSION: Direct injection of sustained-release chemotherapy improves local tumor drug concentration and reaction time, and reduces or avoids systemic chemotherapy-induced common side effects, providing a new route of administration. Direct injection of sustained-release chemotherapy also relieves the pain of advanced cancer patients, bringing a new hope. Sustained-release anti-tumor agents can be used as an ideal slow-release implant in the chemotherapy drugs used in the treatment of liver cancer.

CLC Number: